Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy among the top 5 best cancer hospitals in the world
Gustave Roussy is in 5th position worldwide and 1st hospital outside of the United States, according to the World’s Best Specialized Hospitals 2021 ranking by Newsweek magazine
Published on
According to the World’s Best Specialized Hospitals 2021 ranking by Newsweek magazine, Gustave Roussy is in 5th position worldwide and 1st hospital outside of the United States. This ranking emphasizes the international recognition for excellence in care and powerful research performed by the Institute. It also means that patients, whose decision to choose the right hospital is determined mainly by the hospital’s reputation, can be confident and receive in France both the best care and the most effective clinical research.
"We are proud to be one of the world's top 5 cancer centers along with four American giants. This ranking is an important recognition of our savoir-faire and team expertise. Both our medical staff and scientists play an important part in making French healthcare one of the best in the world. Gustave Roussy has the ability to meet all the challenges of the 21st century: to detect, to study, to fight against, to care for and to overcome cancer" explains Professor Jean-Charles Soria, CEO of Gustave Roussy.
This new ranking reinforces Gustave Roussy's international reputation. Honored every year in the Clarivate ranking, with 10 of its experts featuring in the 2019 list of the world's most "Highly cited researchers". Gustave Roussy's physician-scientists are also regularly awarded prizes at international congresses by learned societies or major research organizations or foundations. Knowledge production is intensive, with 1,800 international publications, including more than 60 in highly cited papers (journal impact factor greater than 30).
Today, the Institute is a key player in the world for early trials, immunotherapy and precision medicine clinical trials. Nearly a quarter of Gustave Roussy's patients are part of a clinical study.
Today, by developing its new institutional strategic plan for the next ten years, Gustave Roussy is all geared up for the fight against cancer and the growing complexity of the disease, all for the benefit of their patients.
More about
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
